LIVE POST COVID-19:

What Does the New Normal

Look Like
Amin soebandrio
Situation in numbers by WHO Region
(WHO SitRep 127; 26 May 2020)
Region Cases (New) Deaths (New)
Globally 5,404,512 (99,780) 343,514 (1,486)
Africa 83,044 (3,042) 2,214 (94)
Americas 2,454,452 (59,157) 143,739 (2,267)
Eastern Mediterranean 438,900 (11,068) 11,293 (129)
Europe 2,041,705 (16,569) 173,213 (-1,215**)
South-East Asia 210,273 (9,066) 6,140 (188)
Western Pacific 175,397 (878) 6,902 (23)
Indonesia 22,750 (479) 1,391 (19)
SitRep Indonesia
27 May 2020
Epidemic Curve of
Individual
Provinces
Where did SARS-CoV-2
https://www.gisaid.org/epiflu-applications/next-hcov-19-
in Indonesia •
app/
come from
 • Fever or chills
Post Covid-19??? • Cough
• Shortness of breath or difficulty
breathing
Diseases • Fatigue
with many • Muscle or body aches
No specific • Headache
faces
anti-virus • New loss of taste or smell
available • Sore throat
• Congestion or runny nose
No specific • Nausea or vomiting
vaccine • Diarrhea
available

SARS-CoV-2 will stay with us

for longer period
CLINICAL-PHASE VACCINE CANDIDATES FOR
COVID-19 Candidate Vaccine characteristics
LNP-encapsulated
Lead developer Status

mRNA-1273 mRNA vaccine encoding Moderna Phase I (NCT04283461)

aAPC, artificial antigen-presenting cell; CTL, cytotoxic T lymphocyte; DC, dendritic cell; LNP, lipid

S protein
nanoparticle; S protein, SARS-CoV-2 spike protein. Source: ClinicalTrials.gov website; WHO.

Adenovirus type 5
Ad5-nCoV vector that expresses S CanSino Biologicals Phase I (NCT04313127)
protein
DNA plasmid encoding S
INO-4800 protein delivered by Inovio Pharmaceuticals Phase I (NCT04336410)
electroporation
DCs modified with
lentiviral vector
expressing synthetic
Shenzhen Geno-
minigene based on
LV-SMENP-DC Immune Medical Phase I (NCT04276896)
domains of selected
Institute
viral proteins;
administered with
antigen-specific CTLs
aAPCs modified with
lentiviral vector
Shenzhen Geno-
expressing synthetic
Pathogen-specific aAPC Immune Medical Phase I (NCT04299724)
minigene based on
Institute
domains of selected
viral proteins
Past Experience
• In the 20th century alone, more than 300
million people died from smallpox until it was
eradicated in 1975 in an effort led by the
World Health Organization.
(https://www.voanews.com/covid-19-pandemic/smallpox-
eradication-40-years-ago-has-parallels-coronavirus-
pandemic)

• The smallpox vaccine, introduced by Edward

Jenner in 1796, was the first successful vaccine
to be developed. He observed that milkmaids
who previously had caught cowpox did not
catch smallpox and showed that inoculated
vaccinia protected against inoculated variola
virus.
(https://www.who.int/csr/disease/smallpox/vaccines/en/)
Our Current “Normals”
Hepatitis

DHF Influenza

HIV

Tuberculosis Malaria
Pre-requisites for a “New Normal”
(http://www.euro.who.int/en/media-centre/sections/statements/2020/statement-transition-to-a-new-normal-during-the-covid-19-pandemic-must-be-guided-by-
public-health-principles)

• That evidence shows COVID-19 transmission is controlled;

• That public health and health system capacities including hospitals are in place
to identify, isolate, test, trace contacts and quarantine them;
• That outbreak risks are minimized in high-vulnerability settings – particularly in
elderly homes, mental health facilities and people residing in crowded places;
• That workplace preventive measures are established – with physical distancing,
handwashing facilities, respiratory etiquette in place;
• That importation risks can be managed; and
• That communities have a voice and are engaged in the transition.
Dr Poonam Khetrapal Singh, Regional
Director, WHO South-East Asia
“Countries in the Region must continue to take
evidence-informed action and conduct careful risk
assessments while winding back public health and
social measures. The focus should be on local
epidemiology of COVID-19, to identify hot-spots and
clusters, and the capacity of systems and responders
to find, isolate and care for cases, and quarantine
contacts,”
https://www.who.int/southeastasia/news/detail/15-05-2020-local-epidemiology-should-guide-
focused-action-in-new-normal-covid-19-world
Charcteristics of New Normal
Standards & Quick detection & Isolation
Working of infected people;
Condition Restricted travel & Social
Distancing

Less
PhysicalContact
Society/Economy
We are not
in the
same boat,
but we are
in the
same
storm